Company: VMCWF
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001641172-25-001827
Chunk: 225

Company: Valuence Merger Corp. I
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1A
Chunk 225
---
 our purchase of its business is contingent on the simultaneous closings of the other business combinations, which may make
it more difficult for us, and delay our ability, to complete our initial Business Combination. With multiple business combinations, we
could also face additional risks, including additional burdens and costs with respect to possible multiple negotiations and due diligence
investigations (if there are multiple sellers) and the additional risks associated with the subsequent assimilation of the operations
and services or products of the acquired companies in a single operating business. If we are unable to adequately address these risks,
it could negatively impact our profitability and results of operations. We do not intend to purchase multiple businesses in unrelated
industries in conjunction with our initial Business Combination.

We
may attempt to complete our initial Business Combination with a private company about which little information is available, which may
result in a Business Combination with a company that is not as profitable as we suspected, if at all.

In
pursuing our acquisition strategy, we may seek to effectuate our initial Business Combination with a privately held company. Very little
public information generally exists about private companies, and we could be required to make our decision on whether to pursue a potential
initial Business Combination on the basis of limited information, which may result in a Business Combination with a company that is not
as profitable as we suspected, if at all.

Because
we intend to seek a Business Combination with a target business or businesses in the healthcare industry and whose principal business
operations are based in Asia (excluding China, Hong Kong and Macau), we expect our future operations to be subject to risks associated
with this industry.

While
we may pursue an acquisition or a target in any business or industry or across any geography, we intend to focus our search for a target
business in healthcare industry and with companies whose principal business operations are based in Asia (excluding China, Hong Kong
and Macau).

38

Life
science related companies (e.g., healthcare, biopharmaceuticals, and digital health) are typically subject to greater governmental regulation
than most other industries whether in the U.S. or global. Industries such as biopharmaceuticals are also the most research-intensive
industries. Many of the risks mentioned associated with these industries involve regulation around research and development (R&D)
of a product or technical risk factors. For example, a healthcare-related company must receive government approval before introducing
new drugs and medical devices or procedures. Drug development and the probability of success through the